The potential role of neoadjuvant chemotherapy in advanced ovarian cancer

International Journal of Gynecological Cancer

Volumn 13, Issue SUPPL. 2, 2003, Pages 163-168

  Baekelandt, M ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

Advanced ovarian cancer; Neoadjuvant chemotherapy; Surgery

Indexed keywords

ANTINEOPLASTIC AGENT; PLATINUM; TAXANE DERIVATIVE;

ADVANCED CANCER; CANCER ADJUVANT THERAPY; CANCER SURVIVAL; CONFERENCE PAPER; FEMALE; HUMAN; MINIMAL RESIDUAL DISEASE; MORBIDITY; OVARY CANCER; PRIORITY JOURNAL; PROGNOSIS; TREATMENT CONTRAINDICATION; TREATMENT INDICATION; TREATMENT OUTCOME;

CLINICAL TRIALS; FEMALE; HUMANS; NEOADJUVANT THERAPY; OVARIAN NEOPLASMS; RESEARCH DESIGN;

EID: 1242320067     PISSN: 1048891X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1525-1438.2003.13354.x     Document Type: Conference Paper

References (42)

1. Silberman AW. Surgical debulking of tumors. Surg Gynecol Obstet 1982;155:577-85.
2. Boente MP, Chi DS, Hoskins WJ. The role of surgery in the management of ovarian cancer: primary and interval cytoreductive surgery. Semin Oncol 1998;25:326-34.
3. Mutch DG. Surgical management of ovarian cancer. Semin Oncol 2002;29:3-8.
4. Vermorken JB. The integration of paclitaxel and new platinum compounds in the treatment of advanced ovarian cancer. Int J Gynecol Cancer 2001;11:21-30.
5. Covens AL. A critique of surgical cytoreduction in advanced ovarian cancer. Gynecol Oncol 2000;78:269-74.
6. Hogberg T. Primary surgery in ovarian cancer: current opinions. Ann Med 1995;27:95-100.
7. Rose PG, Nerenstone S, Brady M et al. A phase III randomized study of interval secondary cytoreduction in patients with advanced stage ovarian carcinoma with suboptimal residual disease: a Gynecologic Oncology Group study. Proc Am Soc Clin Oncol 2002;21:802 [Abstract].
8. Aure JC, Hoeg K, Kolstad P. Clinical and histologic studies of ovarian carcinoma. Long-term follow-up of 990 cases. Obstet Gynecol 1971;37:1-9.
9. Griffiths CT. Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma. J Natl Cancer Inst Monogr 1975;42:101-4.
10. Griffiths CT, Parker LM, Fuller AF. Role of cytoreductive surgical treatment in the management of advanced ovarian cancer. Cancer Treat Rep 1979;63:235-40.
11. Voest EE, van Houwelingen JC, Neijt JP. A meta-analysis of prognostic factors in advanced ovarian cancer with median survival and overall survival (measured with the log (relative risk)) as main objectives. Eur J Cancer Clin Oncol 1989;25:711-20.
12. Bolis G, Villa A, Guarnerio P et al. Survival of women with advanced ovarian cancer and complete pathologic response at second-look laparotomy. Cancer 1996;77: 128-31.
13. Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 2002;20:1248-59.
14. Piver MS, Lele SB, Marchetti DL et al. The impact of aggressive debulking surgery and cisplatin-based chemotherapy on progression-free survival in stage III and IV ovarian carcinoma. J Clin Oncol 1988;6:983-9.
15. Eisenkop SM, Spirtos NM, Montag TW et al. The impact of subspeciality training on the management of advanced ovarian cancer. Gynecol Oncol 1992;47:203-9.
16. Hoskins WJ, McGuire WP, Brady MF et al. The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. Am J Obstet Gynecol 1994;170:974-80.
17. Vergote I, De Wever I, Tjalma W, Van Gramberen M, Decloedt J, Van Dam P. Neoadjuvant chemotherapy or primary debulking surgery in advanced ovarian carcinoma: a retrospective analysis of 285 patients. Gynecol Oncol 1998;71:431-6.
18. LoCoco S, Covens A, Carney M et al. Does aggressive therapy improve survival in suboptimal stage IIIc/IV ovarian cancer? A Canadian-American comparative study. Gynecol Oncol 1995;59:194-9.
19. Hoskins WJ, Bundy BN, Thigpen JT, Omura GA. The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage III epithelial ovarian cancer: a Gynecologic Oncology Group study. Gynecol Oncol 1992;47:159-66.
20. Hacker NF, Berek JS, Lagasse LD et al. Primary cytoreductive surgery for epithelial ovarian cancer. Obstet Gynecol 1983;61:413-20.
21. Heintz AP, Hacker NF, Berek JS et al. Cytoreductive surgery in ovarian carcinoma: feasibility and morbidity. Obstet Gynecol 1986;67:783-8.
22. Farias-Eisner R, Teng F, Oliveira M et al. The influence of tumor grade, distribution, and extent of carcinomatosis in minimal residual stage III ovarian cancer after optimal primary cytoreductive surgery. Gynecol Oncol 1994;55:108-10.
23. van Geene P, Varma R, Dunn J, Chan KK, Luesley DM. The prognostic significance of intraperitoneal growth characteristics in epithelial ovarian carcinoma. Int J Gynecol Cancer 1996;6:219-24.
24. van der Burg ME, van Lent M, Buyse M et al. The effect of debulking surgery after induction chemotherapy on the prognosis in advanced ovarian epithelial cancer. N Engl J Med 1995;332:629-34.
25. Lawton FG, Redman CW, Luesley DM, Chan KK, Blackledge G. Neoadjuvant (cytoreductive) chemotherapy combined with intervention debulking surgery in advanced, unresected epithelial ovarian cancer. Obstet Gynecol 1989;73:61-5.
26. Jacob JH, Gershenson DM, Morris M, Copeland LJ, Bruke TW, Wharton JT. Neoadjuvant chemotherapy and interval debulking for advanced epithelial ovarian cancer. Gynecol Oncol 1991;42:146-50.
27. Onnis A, Marchetti M, Padovan P, Castellan L. Neoadjuvant chemotherapy in advanced ovarian cancer. Eur J Gynaecol Oncol 1996;17:393-6.
28. Surwit E, Childers J, Atlas I et al. Neoadjuvant chemotherapy for advanced ovarian cancer. Int J Gynecol Cancer 1996;6:356-61.
29. Schwartz PE, Rutherford TJ, Chambers JT, Kohorn EI, Thiel RP. Neoadjuvant chemotherapy for advanced ovarian cancer: long-term survival. Gynecol Oncol 1999;72:93-9.
30. Schwartz PE. Neoadjuvant chemotherapy for the management of ovarian cancer. Baillieres Best Pract Res Clin Obstet Gynaecol 2002;16:585-96.
31. Chambers JT, Chambers SK, Voynick IM, Schwartz PE. Neoadjuvant chemotherapy in stage X ovarian carcinoma. Gynecol Oncol 1990;37:327-31.
32. Kayikciog Lu F, Köse MF, Boran N, Caliskan E, Tulunay G. Neoadjuvant chemotherapy or primary surgery in advanced ovarian carcinoma. Int J Gynecol Cancer 2001;11:466-70.
33. Chan YM, Ng TY, Ngan HY, Wong LC. Quality of life in women treated with neoadjuvant chemotherapy for advanced ovarian cancer: a prospective longitudinal study. Gynecol Oncol 2003;88:9-16.
34. Ansquer Y, Leblanc E, Clough K et al. Neoadjuvant chemotherapy for unresectable ovarian carcinoma. Cancer 2001;91:2329-34.
35. Kuhn W, Rutke S, Späthe K et al. Neoadjuvant chemotherapy followed by tumor debulking prolongs survival for patients with poor prognosis in International Federation of Gynecology and Obstetrics stage IIIc ovarian carcinoma. Cancer 2001;92:2585-91.
36. Nelson BE, Rosenfield AT, Schwartz PE. Preoperative abdominopelvic computed tomographic prediction of optimal cytoreduction in epithelial ovarian carcinoma. J Clin Oncol 1993;11:166-72.
37. Meyer JI, Kennedy AW, Friedman R, Ayoub A, Zepp RC. Ovarian carcinoma: value of CT in predicting success of debulking surgery. AJR Am J Roentgenol 1995;165:875-8.
38. Bristow RE, Duska LR, Lambrou NC et al. A model for predicting surgical outcome in patients with advanced ovarian carcinoma using computed tomography. Cancer 2000;89:1532-40.
39. Chi DS, Venkatraman ES, Masson V, Hoskins WJ. The ability of preoperative serum ca-125 to predict optimal primary tumor cytoreduction in stage III epithelial ovarian carcinoma. Gynecol Oncol 2000;77:227-31.
40. Saygili U, Guclu S, Uslu Tet al. Can serum CA-125 levels predict the optimal primary cytoreduction in patients with advanced ovarian carcinoma? Gynecol Oncol 2002;86:57-61.
41. Kadar N. Port-site recurrences following laparoscopic operations for gynaecological malignancies. Br J Obstet Gynaecol 1997;104:1308-13.
42. Eisenkop SM, Spirtos NM. Procedures required to accomplish complete cytoreduction of ovarian cancer: is there a correlation with "biological aggressiveness" and survival? Gynecol Oncol 2001;82:435-41.